News
This agreement includes the evaluation, development and marketing of several therapeutic peptides from the AplaGen pipeline. The peptides will be used in the veterinary field only.
AplaGen will bring in its know how for development and synthesis ofpeptides as well as patented compounds and research capacities into thecooperation. Bayer will be responsible for preclinical and clinicaldevelopment and worldwide marketing.
Dr. Franzpeter Bracht and Prof. Dr. Hans-Georg Frank, managing directors of AplaGen GmbH, welcome the closing of the agreement. "With Bayer HealthCareAG, we have found a strong leader of the industry as our partner."
AplaGen GmbH is a venture capital financed biotechnology company, located in Baesweiler, Germany. AplaGen GmbH is specialised on the evaluation and development of therapeutic peptides that can be used for different indications. AplaGen possesses a broad patent portfolio which is based on compounds as well as on peptide technologies.
Contacts:
Dr. Franzpeter Bracht
Dr. Silke Behne
AplaGen GmbH
Arnold-Sommerfeld-Ring 2
52499 Baesweiler
Tel: +49 2401 805 570
Fax:+49 2401 805574
Visit also: www.Aplagen.com
